Armata Pharmaceuticals (ARMP) Total Debt (2018 - 2026)

Armata Pharmaceuticals has disclosed Total Debt across 7 years of filings, most recently posting $88.0 million for Q1 2026.

• Total Debt for Q1 2026 came in at $88.0 million, up 217.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.0 million (up 217.67% YoY), and the FY2025 annual result was $103.1 million, up 357.26% from the prior year.
• Total Debt came in at $88.0 million for Q1 2026 at Armata Pharmaceuticals, down from $103.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $107.0 million in Q1 2024 to a low of $22.3 million in Q3 2023.
• The 4-year median for Total Debt is $41.4 million (2024), against an average of $52.8 million.
• Peak annual rise in Total Debt reached 357.26% in 2025, while the deepest fall reached 74.12% in 2025.
• Armata Pharmaceuticals' Total Debt stood at $23.7 million in 2023, then declined by 4.79% to $22.5 million in 2024, then soared by 357.26% to $103.1 million in 2025, then slipped by 14.64% to $88.0 million in 2026.
• The last three Total Debt figures came in at $88.0 million (Q1 2026), $103.1 million (Q4 2025), and $63.3 million (Q3 2025), per Business Quant data.